June Almenoff has been appointed chief operating officer and chief medical officer of Innovate Biopharmaceuticals (NASDAQ: [[ticker:INNT]]). Almenoff’s experience includes serving as chief medical officer of Furiex Pharmaceuticals, as well as various positions at GlaxoSmithKline (NYSE: [[ticker:GSK]]). Raleigh, NC-based Innovate’s lead drug, larazotide acetate, is being prepared to start Phase 3 studies testing it as a treatment for celiac disease.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
